Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GPR183 | P32249 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18533705 | 0.78 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL25936320 | 0.78 | THRA (0.47) | PIK3CD | |
| SCHEMBL27438918 | 0.76 | — | — | |
| SCHEMBL27702215 | 0.74 | CES2 (0.52) | TSHR | |
| Formic Acid SCHEMBL10486291 | 0.73 | TSHR (0.46) | PIK3CDTSHR | |
| SCHEMBL16095403 | 0.73 | — | — | |
| SCHEMBL28822104 | 0.73 | MAPT (0.31) | — | |
| SCHEMBL28686853 | 0.73 | CHRNB2 (0.37) | PIK3CDTSHRGPR183KCNH2 | |
| SCHEMBL15477012 | 0.70 | — | — | |
| SCHEMBL15130168 | 0.70 | CHRNB2 (0.41) | PIK3CDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618895-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| US-20180065959-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065959-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | PC, BAD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PIK3CD 2067/4885TSHR 3290/4885GPR183 1239/4885 |
| US-10618895-B2 | Bicyclic heterocycle compounds and their uses in therapy | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PC | PIK3CD 1810/4885TSHR 3194/4885GPR183 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.